Biotech stocks remain on many investors’ radar and for good reasons. Biotech companies are usually more insulated from global events such as the ongoing COVID-19 pandemic and economic uncertainty.

The company had planned to sell 13.6 million shares in the range of $28 to $31 apiece. The IPO haul was about $500 million. The biotech’s shares will trade on the Nasdaq under the stock symbol ...

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for ...

Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments.

The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves ...

Insider buying A less-risky approach to biotech is to invest in large-cap biopharma stocks. These two companies saw corporate insiders recently buying stock. Pfizer Inc. (PFE): Pfizer's size and ...